Abatacept
Orencia (Bristol-Myers Squibb)
Abatacept — Approved Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Rheumatoid arthritis — moderate to severe | Adults | Monotherapy or with MTX/non-biologic DMARDs | FDA Approved (2005) |
| Polyarticular JIA — moderate to severe | ≥2 years (SC); ≥6 years (IV) | Monotherapy or with MTX | FDA Approved |
| Psoriatic arthritis | Adults and ≥2 years (SC) | Monotherapy or with non-biologic DMARDs | FDA Approved (ped SC: 2023) |
| Acute GVHD prophylaxis | Adults and ≥2 years | With CNI + MTX; matched/1-allele-mismatched unrelated-donor HSCT | FDA Approved (2021) |
Abatacept is the only T-cell co-stimulation modulator approved for rheumatologic conditions. Unlike TNF-α inhibitors, it acts upstream in the inflammatory cascade by blocking the CD80/CD86-to-CD28 co-stimulatory interaction required for full T-cell activation. This distinct mechanism makes abatacept a first-line biologic DMARD option alongside TNF inhibitors per ACR 2021 guidelines, and it is particularly relevant for patients who have failed or cannot tolerate anti-TNF therapy. Abatacept was first approved in the US in 2005 for RA, with subsequent indications for pJIA, PsA, and aGVHD prophylaxis.
Abatacept is frequently co-positioned with TNF inhibitors in guidelines, but its mechanism is fundamentally different. It modulates the upstream T-cell co-stimulatory signal rather than blocking a single downstream cytokine. This distinction is clinically meaningful: abatacept does not carry a boxed warning for serious infections and malignancy (unlike TNF inhibitors), has an especially favourable safety profile in COPD-free patients, and demonstrates particular efficacy in anti-CCP-positive and RF-positive RA populations. However, it must NOT be combined with TNF blockers, other biologics, or JAK inhibitors due to additive immunosuppression.
Abatacept Dosing by Clinical Scenario
Intravenous (Weight-Tiered) — Adult RA and PsA
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| RA / PsA — <60 kg | 500 mg IV at Wk 0, 2, 4 | 500 mg IV Q4W | 500 mg Q4W | 30-minute infusion; with MTX or non-biologic DMARDs Approximately 10 mg/kg weight-tiered |
| RA / PsA — 60–100 kg | 750 mg IV at Wk 0, 2, 4 | 750 mg IV Q4W | 750 mg Q4W | Most common weight tier; uses 3 vials (3 × 250 mg) |
| RA / PsA — >100 kg | 1000 mg IV at Wk 0, 2, 4 | 1000 mg IV Q4W | 1000 mg Q4W | Uses 4 vials; ensure final concentration ≤10 mg/mL |
Subcutaneous (Fixed Dose) — Adult RA and PsA
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| RA — with or without IV loading | 125 mg SC weekly | 125 mg SC QW | 125 mg QW | Optional single IV loading dose (weight-tiered) on Day 1 before first SC dose IV loading not required for PsA |
| PsA — SC | 125 mg SC weekly | 125 mg SC QW | 125 mg QW | No IV loading dose required; with or without non-biologic DMARDs |
The fixed 125 mg weekly SC dose is therapeutically equivalent to the weight-tiered IV regimen in RA. SC abatacept can be self-administered at home after training, reducing healthcare visits. When switching from IV to SC, give the first SC dose in place of the next scheduled IV infusion. The optional IV loading dose before SC therapy is available for RA but is not required, and is not used for PsA.
Pharmacology
Mechanism of Action
Abatacept is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 linked to the modified Fc portion of human IgG1. It selectively modulates T-cell activation by binding to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells, thereby blocking the co-stimulatory interaction between CD80/CD86 and CD28 on T cells. Without this second signal, full T-cell activation does not occur, leading to reduced T-cell proliferation, decreased cytokine production (including TNF-α, interferon-γ, and IL-2), and downstream suppression of the inflammatory cascade. Abatacept does not directly deplete T cells or B cells, and it does not neutralise TNF-α — it acts upstream of the cytokine network. This upstream mechanism may explain its more gradual onset of action compared to TNF inhibitors (clinical improvement often takes 8–12 weeks to become apparent).
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | SC bioavailability ~78.6% (relative to IV); SC Cminss ~32.5 mcg/mL; Cmaxss ~48.1 mcg/mL; linear PK | High SC bioavailability supports fixed weekly dosing without weight adjustment |
| Distribution | Vd ~0.11 L/kg; increases with body weight; primarily intravascular | Weight-tiered IV dosing needed to ensure comparable trough across weight groups |
| Metabolism | Exact pathway unknown; presumed catabolism by reticuloendothelial system; not CYP-mediated | MTX, NSAIDs, corticosteroids do not influence clearance (pop PK); no conventional drug interactions |
| Elimination | Terminal t½ ~14.3 days; clearance 0.28 mL/h/kg; clearance increases linearly with body weight | Steady state by ~day 60 (IV); Cminss ≥10 mcg/mL associated with near-maximal efficacy |
Side Effects
Data below are from placebo-controlled IV abatacept studies in RA (1,955 patients abatacept, 989 placebo; Studies I–VI; FDA PI), unless otherwise stated. SC safety profile is consistent with IV.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | ≥10% | Most commonly reported AE; generally mild to moderate |
| Upper respiratory tract infection | ~13% | Part of the broader infection signal (54% total vs 48% placebo) |
| Nasopharyngitis | ~12% | 11.8% abatacept vs 10.0% placebo in Canadian product monograph |
| Nausea | ≥10% | Generally mild; rarely led to discontinuation |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Sinusitis | 5–13% | Included among the most commonly reported infections |
| Urinary tract infection | 5–13% | Treat promptly; monitor for recurrence |
| Influenza | 5–13% | Ensure annual influenza vaccination (inactivated) |
| Bronchitis | 5–13% | Part of respiratory infection spectrum |
| Dizziness | ≥5% | Reported in Aetna/BMS summary of common AEs |
| Hypertension | ≥5% | Monitor blood pressure periodically |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Serious infections (pneumonia, cellulitis, UTI, pyelonephritis, diverticulitis) | 3.0% vs 1.9% placebo | Any time during treatment | Discontinue abatacept; initiate appropriate antimicrobials |
| COPD exacerbation (in COPD patients) | 8% (3/37) vs 0% placebo in Study V | During treatment | Use with caution in COPD; monitor respiratory status; discontinue if worsening |
| Malignancy (overall) | 1.2% vs 0.9% placebo | Months to years | Lung cancer 0.2% vs 0%; lymphoma rate higher than general population; periodic skin examination |
| Infusion reactions (IV) | Uncommon; discontinuation 0.3% vs 0.1% | Within 1 hour of infusion | Slow or stop infusion; treat symptomatically; anaphylaxis very rare |
| Infections with concomitant TNF blocker use | 63% (vs 43% TNFi alone); SAE 4.4% vs 0.8% | Throughout treatment | Do NOT combine abatacept with TNF blockers, biologics, or JAK inhibitors |
In Study V, COPD patients treated with abatacept experienced adverse events more frequently than placebo (97% vs 88%). Respiratory disorders occurred in 43% vs 24%, including COPD exacerbation, cough, rhonchi, and dyspnoea. Serious adverse events occurred in 27% vs 6%, including COPD exacerbation (8%) and pneumonia (3%). Abatacept should be used with caution in COPD patients, with close monitoring of respiratory status.
Drug Interactions
Abatacept is not metabolised by CYP450 enzymes. Population PK analyses confirmed that MTX, NSAIDs, corticosteroids, and TNF blockers did not influence abatacept clearance. The most significant interactions are pharmacodynamic, relating to additive immunosuppression.
Monitoring
- TB ScreeningBefore initiation
RoutineTST or IGRA before starting. Treat latent TB before initiation. - Hepatitis B & CBefore initiation
RoutineScreen all patients before starting. Monitor HBV carriers during therapy. - Signs of InfectionEvery visit
RoutineInfections in 54% vs 48% placebo. Monitor for fever, cough, UTI symptoms, herpes zoster. - Vaccination StatusBefore initiation
RoutineUpdate all vaccinations before starting. No live vaccines during or within 3 months after discontinuation. Abatacept may blunt response to some immunisations. - Skin ExaminationPeriodically
RoutineNon-melanoma skin cancers reported. Periodic skin examination recommended, particularly in those with risk factors. - Respiratory StatusIf COPD present
Trigger-BasedCOPD patients: AEs 97% vs 88%; respiratory disorders 43% vs 24%. Monitor closely for COPD exacerbation, dyspnoea, cough. - Blood GlucoseOn IV infusion days (diabetic patients)
Trigger-BasedIV formulation contains maltose; may cause falsely elevated glucose with certain test strips (GDH-PQQ). Use glucose-specific methods. SC formulation does not contain maltose.
Contraindications & Cautions
Absolute Contraindications
- None listed in the US FDA label. Canadian labelling adds: hypersensitivity to abatacept or any excipient; patients with, or at risk of, sepsis syndrome (immunocompromised, HIV positive).
Relative Contraindications (Specialist Input Recommended)
- Active serious infection — do not initiate until fully controlled.
- Concurrent use with TNF blockers, other biologics, or JAK inhibitors — significantly increased infection risk without benefit.
- History of recurrent infections — careful risk-benefit assessment.
Use with Caution
- COPD — substantially increased respiratory AE rate (97% vs 88%); use with caution and monitor closely.
- Elderly (≥65 years) — higher infection risk in the general geriatric population.
- Pregnancy — limited human data; animal studies showed immune effects in offspring; not recommended by ACR/EULAR during pregnancy.
- Diabetes (IV infusion) — maltose content may interfere with glucose monitoring.
Concurrent therapy with abatacept and a TNF antagonist is not recommended. In controlled trials, adult RA patients receiving concomitant abatacept and TNF antagonist therapy experienced substantially more infections (63%) and serious infections (4.4%) compared to patients on TNF antagonist alone (43% and 0.8%, respectively), without meaningful improvement in efficacy over TNF antagonist monotherapy.
Patient Counselling
Purpose of Therapy
Abatacept works differently from other biologic treatments for arthritis. Instead of blocking a single inflammatory molecule like TNF, it prevents the activation of T cells — immune cells that drive the inflammation underlying rheumatoid arthritis and psoriatic arthritis. By calming these T cells, abatacept reduces joint pain, stiffness, and swelling, and can slow joint damage over time. Improvement may take 8–12 weeks to become noticeable.
How to Take
Abatacept is available as either a monthly intravenous infusion given at a clinic (over 30 minutes) or a weekly injection under the skin that you can do at home using a prefilled syringe or autoinjector (ClickJect). Subcutaneous injections should be given in the thigh or abdomen, rotating sites each time. Store in the refrigerator; do not freeze. Allow the syringe to reach room temperature (30–60 minutes) before injecting.
Sources
- Bristol-Myers Squibb. ORENCIA (abatacept) for injection, for intravenous use; injection, for subcutaneous use. Full Prescribing Information. 2021. FDA LabelPrimary source for all dosing, indications, adverse reactions, PK data, and immunogenicity across RA, pJIA, PsA, and aGVHD.
- Bristol-Myers Squibb. ORENCIA (abatacept). US Prescribing Information. 2024. BMS PIMost current label including PsA pediatric SC indication (October 2023).
- Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition (ATTAIN). N Engl J Med. 2005;353(11):1114-1123. doi:10.1056/NEJMoa050524Landmark Study IV establishing abatacept efficacy in TNFi-IR RA patients; pivotal for approval.
- Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis (AIM). Ann Intern Med. 2006;144(12):865-876. doi:10.7326/0003-4819-144-12-200606200-00003Study III demonstrating ACR50/70 responses and inhibition of radiographic progression with abatacept + MTX in MTX-IR patients.
- Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86-94. doi:10.1136/annrheumdis-2013-203843Head-to-head trial showing SC abatacept non-inferior to adalimumab in MTX-IR RA with comparable 2-year safety.
- Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early RA (AVERT). Ann Rheum Dis. 2015;74(1):19-26. doi:10.1136/annrheumdis-2014-206106AVERT trial in early RA supporting abatacept + MTX for induction of DAS28 remission and feasibility of drug-free remission.
- Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early RA and poor prognostic factors (AGREE). Ann Rheum Dis. 2009;68(12):1870-1877. doi:10.1136/ard.2008.101121AGREE trial in MTX-naive early RA showing DAS28 remission and radiographic non-progression with abatacept + MTX.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939. doi:10.1002/acr.24596Current ACR guideline positioning abatacept alongside TNF inhibitors as a preferred first biologic DMARD after csDMARD failure.
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of RA: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356EULAR consensus supporting abatacept as a biologic option after csDMARD failure in RA.
- Li J, Manikhas GM, Hsia EC, et al. Population pharmacokinetics and exposure–response relationship of intravenous and subcutaneous abatacept in patients with rheumatoid arthritis. J Clin Pharmacol. 2019;59(6):876-885. doi:10.1002/jcph.1308Pop PK/E-R model confirming weight-tiered IV dosing rationale and 10 mcg/mL trough threshold for near-maximal efficacy.
- Genovese MC, Pacheco-Tena C, Covarrubias A, et al. Safety of abatacept versus placebo in rheumatoid arthritis: integrated data from nine clinical trials. ACR Open Rheumatol. 2019;1(8):519-529. doi:10.1002/acr2.11071Pooled safety analysis of 9 RCTs (2,653 abatacept vs 1,485 placebo) confirming comparable AE/SAE rates to placebo.